Legler, Tobias J.

[["dc.bibliographiccitation.firstpage","533"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Archives of Gynecology and Obstetrics"],["dc.bibliographiccitation.lastpage","537"],["dc.bibliographiccitation.volume","279"],["dc.contributor.author","Grill, Simon"],["dc.contributor.author","Banzola, Irina"],["dc.contributor.author","Li, Ying"],["dc.contributor.author","Rekhviashvili, Tea"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Mueller, Sina Patricia"],["dc.contributor.author","Zhong, Xiao Yan"],["dc.contributor.author","Hahn, Sinuhe"],["dc.contributor.author","Holzgreve, Wolfgang"],["dc.date.accessioned","2018-11-07T08:30:51Z"],["dc.date.available","2018-11-07T08:30:51Z"],["dc.date.issued","2009"],["dc.description.abstract","To examine the potential high throughput capability and efficiency of an automated DNA extraction system in combination with mass spectrometry for the non-invasive determination of the foetal Rhesus D status. A total of 178 maternal plasma samples from RHD-negative pregnant women were examined, from which DNA was extracted using the automated Roche MagNA Pure (TM) system. Presence of the foetal RHD gene was detected by PCR for RHD exon 7 and subsequent analysis using the Sequenom MassArray (TM) mass spectrometric system. We determined that as little as 15 pg of RHD-positive genomic DNA could be detected in a background of 585 pg of RHD-negative genomic DNA. The analysis of the clinical samples yielded a sensitivity and specificity of 96.1 and 96.1%, respectively. Our study indicated that automated DNA extraction in combination with mass spectrometry permits the determination of foetal Rhesus D genotype with an accuracy comparable to the current approaches using real-time PCR."],["dc.identifier.doi","10.1007/s00404-008-0774-5"],["dc.identifier.isi","000263670600016"],["dc.identifier.pmid","18751991"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16993"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","0932-0067"],["dc.title","High throughput non-invasive determination of foetal Rhesus D status using automated extraction of cell-free foetal DNA in maternal plasma and mass spectrometry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1300"],["dc.bibliographiccitation.issue","13"],["dc.bibliographiccitation.journal","Prenatal Diagnosis"],["dc.bibliographiccitation.lastpage","1304"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Mueller, Sina Patricia"],["dc.contributor.author","Bartels, Iris"],["dc.contributor.author","Stein, Werner"],["dc.contributor.author","Emons, Guenter"],["dc.contributor.author","Gutensohn, Kai"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T08:49:16Z"],["dc.date.available","2018-11-07T08:49:16Z"],["dc.date.issued","2011"],["dc.description.abstract","Objective Before noninvasive prenatal diagnosis on the fetal Rhesus D status (NIPD RhD) can be implemented on a mass-scale, it is crucial to define requirements regarding sample transport. The aim of this study was to determine the relation between the transport time of samples for NIPD and the concentration of fetal DNA in maternal plasma. Method We analyzed qualitative and quantitative data obtained in a previous study performed with real-time PCR to determine the accuracy of NIPD RhD following two different DNA extraction protocols. The number of days from phlebotomy until freezing of plasma at the study site was recorded and defined as transport time. Results NIPD RhD results of 972 specimens were analyzed according to transport time, which varied from a few hours to a maximum of 8 days (median 2 days). No decrease of cell-free fetal DNA was observed in samples with less than 6 days transport time. There was a pivotal trend to higher cycle threshold values in samples with >= 6 days transport time compared with those with <= 5 days. Conclusion Because only a few laboratories offer an NIPD RhD service, we suggest a maximal transport time of 5 days from phlebotomy until freezing at the testing laboratory. Copyright (C) 2011 John Wiley & Sons, Ltd."],["dc.description.sponsorship","European Commission; Network of Excellence [LSHB-CT-2004-503243]"],["dc.identifier.doi","10.1002/pd.2889"],["dc.identifier.isi","000298566900014"],["dc.identifier.pmid","22030893"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21416"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","0197-3851"],["dc.title","Cell-free fetal DNA in specimen from pregnant women is stable up to 5?days"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","722"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","BJOG An International Journal of Obstetrics & Gynaecology"],["dc.bibliographiccitation.lastpage","729"],["dc.bibliographiccitation.volume","117"],["dc.contributor.author","Gutensohn, Kai"],["dc.contributor.author","Mueller, Sina Patricia"],["dc.contributor.author","Thomann, K."],["dc.contributor.author","Stein, W."],["dc.contributor.author","Suren, A."],["dc.contributor.author","Koertge-Jung, S."],["dc.contributor.author","Schlueter, G."],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T08:43:24Z"],["dc.date.available","2018-11-07T08:43:24Z"],["dc.date.issued","2010"],["dc.description.abstract","Objective The aim of the study was to determine the sensitivity, specificity and accuracy of noninvasive tests for the fetal rhesus CcEc (RHCE) alleles C, c and E in early pregnancy. Design A prospective clinical trial was carried out to evaluate diagnostic accuracy. Setting Women were recruited at four centres specialising in prenatal diagnosis. Peripheral blood and amniotic fluid samples were obtained and sent to a single laboratory for analysis. Sample A total of 233 tests (46 for C, 87 for c and 100 for E) were performed on 181 specimens obtained from pregnant women at weeks 12 to 28 (median week 16) of gestation. Methods Following automated extraction of fetal DNA from maternal plasma, two different real-time polymerase chain reaction (PCR) protocols were used for the detection of the C, c and E alleles of RHCE. The results of the PCR were compared with genotyping results for the amniotic fluid. Main outcome measures Failure rate, sensitivity, specificity and accuracy were the main outcome measures. Results Unequivocal results were obtained for all specimens. With the first PCR protocol, the sensitivity was 100% for C, 38% for c and 59% for E. In contrast, with the second protocol, the sensitivity for C, c and E was 100%. The specificity for all assays was found to be between 99% and 100%. Conclusions A highly accurate protocol has been identified for the detection of fetal RHCE alleles in maternal plasma in early pregnancy. This noninvasive approach can be considered as a useful test in the management of pregnancies with anti-c, anti-E or anti-C alloimmunisation."],["dc.identifier.doi","10.1111/j.1471-0528.2010.02518.x"],["dc.identifier.isi","000276509100011"],["dc.identifier.pmid","20175873"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6291"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19957"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1470-0328"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Diagnostic accuracy of noninvasive polymerase chain reaction testing for the determination of fetal rhesus C, c and E status in early pregnancy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2292"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Transfusion"],["dc.bibliographiccitation.lastpage","2301"],["dc.bibliographiccitation.volume","48"],["dc.contributor.author","Mueller, Sina Patricia"],["dc.contributor.author","Bartels, Iris"],["dc.contributor.author","Stein, Werner"],["dc.contributor.author","Emons, Guenther"],["dc.contributor.author","Gutensohn, Kai"],["dc.contributor.author","Koehler, Michael"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T11:09:47Z"],["dc.date.available","2018-11-07T11:09:47Z"],["dc.date.issued","2008"],["dc.description.abstract","Noninvasive fetal RHD genotyping might become a valuable tool in decision making on antenatal Rh prophylaxis, which is currently in routine practice for all D- pregnancies in several countries. This study provides a large-scale validation study of this technology to address questions concerning feasibility and applicability of its introduction into clinical routine. Real-time polymerase chain reaction (PCR) targeting RHD Exons 5 and 7 was applied for the detection of fetal-specific RHD sequences in maternal plasma. A total of 1113 women in 6 to 32 weeks (median, Week 25) of pregnancy were recruited. All of them were serologically typed as D- according to current German guidelines. DNA was extracted via a spin-column method and a novel automated approach using magnetic tips. Real-time PCR results were compared with postnatal serology and discrepancies further elucidated by DNA sequencing from a newborn's buccal swab. Sensitivities of fetal RHD genotyping were 99.7 percent (spin columns) and 99.8 percent (magnetic tips), thus comparable with serology (99.5%). The detection of weak D variants was more reliable by real-time PCR. Specificities of fetal RHD genotyping were 99.2 percent (spin columns) and 98.1 percent (magnetic tips), which is lower than serology (> 99.7%). Automation achieved significantly higher yields of cell-free fetal DNA. This prospective clinical trial revealed that routine determination of the fetal D status from maternal plasma is feasible. Noninvasive fetal RHD genotyping can be considered as sensitive as the traditional postnatal serologic assay."],["dc.identifier.doi","10.1111/j.1537-2995.2008.01843.x"],["dc.identifier.isi","000261086200007"],["dc.identifier.pmid","18694461"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6289"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53084"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing"],["dc.relation.issn","0041-1132"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","189"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Transfusion Medicine and Hemotherapy"],["dc.bibliographiccitation.lastpage","198"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Mueller, Sina Patricia"],["dc.contributor.author","Haverkamp, Alexander"],["dc.contributor.author","Grill, Simon"],["dc.contributor.author","Hahn, Sinuhe"],["dc.date.accessioned","2018-11-07T08:35:34Z"],["dc.date.available","2018-11-07T08:35:34Z"],["dc.date.issued","2009"],["dc.description.abstract","The availability of noninvasive prenatal diagnosis for the fetal RhD status (NIPD RhD) is an obvious benefit for alloimmunized pregnant women. This review gives information about the performance characteristics of current diagnostic technologies and recent promising proof-of-principle studies. Notably, during the past 3 years almost twice as much samples have been investigated with NIPD RhD compared with the studies from 1998 to 2005. Thus we have now a lot more information compared with the knowledge before 2006. There is no doubt that funding of the SAFE Network of Excellence (2004-2009) from the European Commission within the framework 6 program has massively increased the worldwide experience in NIPD RhD. In 2009 European funding has been stopped. Because of this large investment from public funding sources, it is now the duty of policy makers (scientific boards, patient groups, physician organizations, and health assurances) to discuss if targeted antenatal Rh prophylaxis should be introduced in German-speaking countries or which additional data are required to make a decision and how these additional studies should be funded."],["dc.identifier.doi","10.1159/000216580"],["dc.identifier.isi","000266883700006"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/9348"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18101"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","1660-3796"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Prenatal RhD Testing: A Review of Studies Published from 2006 to 2008"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]